KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
Titel:
KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
Auteur:
Lonial, S. Ribeiro de Oliveira, M. Yimer, H. Mateos, M.V. Rifkin, R. Schjesvold, F. San-Miguel, J. Ghori, R. Marinello, P. Jagannath, S.